In a recent study published in The Lancet Diabetes Endocrinology, researchers evaluate the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes.
Improving kidney and cardiovascular outcomes
Non-communicable diseases account for nearly 70% of global deaths, with diabetes and chronic kidney disease (CKD) among the top causes.
Leave a reply